Monitoring of controlled ovarian stimulation in IVF
DOI:10.1007/s10815-024-03182-x by Journal of Assisted Reproduction and Genetics in 2024
[1024]
TextBook
Individualised dosing of follitropin delta affects live birth and safety in IVF: an individual participant data meta-analysis of randomised controlled trials
DOI:10.1016/j.fertnstert.2024.05.143 by Fertility and Sterility in 2024
[854]
Efficacy and safety of follitropin delta versus follitropin alpha/beta in infertility treatment: A systematic review and meta-analysis
DOI:10.1002/rmb2.12573 by Reproductive Medicine and Biology in 2024
[797]
Using GnRH agonists in combination with hCG in antagonist ART cycles: A SCOPING Review of recent evidences
DOI:https://www.jbra.com.br/media/html/JBRA2377.html by JBRA Assisted Reproduction in 2023
[562]
Progestin primed ovarian stimulation, for whom, when and how?
DOI:/10.1016/j.rbmo.2023.103639 by Reproductive BioMedicine Online in 2023
[497]
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
DOI:10.1002/14651858.CD005070.pub3 by Cochrane Database Syst Rev. in 2017
[166]
Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).
DOI:10.1002/14651858.CD005289.pub4 by Cochrane Database Syst Rev. in 2021
[165]
Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
DOI:10.1186/s12958-021-00759-4 by Reproductive Biology and Endocrinology in 2021
[137]
Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis.
DOI:10.1016/j.rbmo.2021.12.006 by Reproductive BioMedicine Online in 0
[91]
Recent Publications
Ovarian Stimulation Effects on Ghrelin Secretion and Reproductive Potential
DOI:10.1111/cen.15167 by Clinical Endocrinology in 2024
[2317]
Adjuvant letrozole administration in gonadotropin releasing hormone antagonist cycles do not affect ploidy status of embryos
DOI:10.1016/j.jogoh.2023.102689 by Journal of Gynecology Obstetrics and Human Reproduction in 2024
[2251]
Impact of letrozole co-treatment in an antagonist protocol for IVF/ICSI: a retrospective study
DOI:10.1186/s12958-024-01297-5 by Reproductive Biology and Endocrinology in 2024
[2153]
From patient classification to optimized treatment in ART: the AMPLITUDE Delphi consensus
DOI:10.3389/frph.2024.1467322 by Frontiers in Reproductive Health in 2024
[2137]
Impact of GnRH antagonist pretreatment on oocyte yield after ovarian stimulation: A retrospective analysis
DOI:10.1371/journal.pone.0308666 by PLoS One. in 2024
[2131]
Dual trigger or hCG alone: A retrospective analysis on patients with diminished ovarian reserve under in vitro fertilization and embryo transfer (IVF-ET) treatment
DOI:10.1016/j.ejogrb.2024.09.039 by European Journal of Obstetrics & Gynecology and Reproductive Biology in 2024
[2097]
The Additive Effect of Combinations of FSH Receptor Gene Variants in Ovarian Response to Stimulation
DOI:10.1007/s43032-024-01700-x by Reproductive Science in 2024
[2024]
Programing the onset of ovarian stimulation: From early follicular phase start to oral contraceptive (OC) pill, to luteal phase E2, Duo-Stim and random start OS protocols
DOI:10.1016/j.fertnstert.2024.09.011 by Fertility and Sterility in 2024
[1941]
Letrozole co-treatment in an antagonist protocol for overweight women undergoing IVF treatment: a retrospective study
DOI:10.1186/s12884-024-06795-3 by BMC Pregnancy and Childbirth in 2024
[1916]
DuoStim: do we have enough evidence to use it?
DOI:10.1016/j.fertnstert.2024.08.333 by Fertility and Sterility in 2024
[1915]
Luteinizing hormone supplementation with human menopausal gonadotropin versus low dose human chorionic gonadotropin during ovarian stimulation does not affect live birth rates after fresh and frozen embryo transfer
DOI:10.1111/jog.16065 by Journal of Obstetrics and Gynaecology Research in 2024
[1897]
GnRH agonist-only trigger, compared to dual trigger, reduces oocyte retrieval rate in high responders without affecting cumulative live birth rate
DOI:10.3389/fendo.2024.1461317 by Frontiers in Endocrinology (Lausanne) in 2024
[1864]
Exposure of antral follicles to medroxyprogesterone acetate during stimulation does not cause molecular perturbations in gonadotropin-responsiveness and steroidogenic function of granulosa cells in progestin-primed cycles
DOI:10.1093/humrep/deae189 by Human Reproduction in 2024
[1773]
Effect of LH level on HCG trigger day on clinical outcomes in patients with diminished ovarian reserve undergoing GnRH-antagonist protocol
DOI:10.1186/s12958-024-01280-0 by Reproductive Biology and Endocrinology in 2024
[1765]
Unexpected poor oocyte retrieval: The phenomenon of the borderline response to the Gonadotropin Releasing Hormone (GnRH) agonist trigger
DOI:10.1016/j.xfre.2024.08.001 by F&S Reports, in 2024
[1749]
Economic evaluation of GnRH-agonist long protocol and GnRH-antagonist protocol in IVT/ICSI among the Chinese population: using pharmacoeconomic models
DOI:10.1136/bmjopen-2023-079715 by BMJ Open. in 2024
[1711]
Extended versus conventional letrozole regimen in patients with polycystic ovary syndrome undergoing their first ovulation induction cycle: a prospective randomized controlled trial
DOI:10.1093/hropen/hoae046 by Human Reproduction Open in 2024
[1605]
The good, the bad and the ugly of luteal phase stimulations
DOI:10.1016/j.rbmo.2024.104383 by Reproductive BioMedicine Online in 2024
[1542]
Comparison of Adding Sildenafil Versus Estradiol to Clomiphene Citrate on the Applebaum Score and Pregnancy Rate in Patients With Unexplained Infertility: A Double-Blind Randomized Controlled Trial
DOI:10.7759/cureus.63414 by Cureus. in 2024
[1532]
Can We Harvest More Mature Oocytes by Repeating Gonadotropin-Releasing Hormone Agonist Doses in Polycystic Ovarian Syndrome Patients at Risk of OHSS in Antagonist Cycles? A Randomised Clinical Trial
DOI:10.22074/ijfs.2023.2008905.1513 by International Journal of Fertility & Sterility in 2024
[1468]
Undetected, natural conception pregnancies in luteal phase stimulations—case series and review of literature
DOI:10.1093/humrep/deae165 by Human Reproduction in 2024
[1420]
Reproductive Outcomes of Dual Trigger versus hCG Alone in Women Undergoing In Vitro Fertilization with Fresh Embryo Transfer Cycles
DOI:10.1155/2024/9972437 by Obstetrics and Gynecology International in 2024
[1412]
Pretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial
DOI:10.1093/humrep/deae167 by Human Reproduction in 2024
[1406]
Gonadotropin-Releasing Hormone (GnRH) Agonist Protocol Improves Pregnancy Outcomes During In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Treatment in Young Infertile Women: A Retrospective Study
DOI:10.7759/cureus.61554 by Cureus. in 2024
[1310]
Monitoring of controlled ovarian stimulation in IVF
DOI:10.1007/s10815-024-03182-x by Journal of Assisted Reproduction and Genetics in 2024
[1302]
Co-administration of GnRH-agonist and hCG (double trigger) for final oocyte maturation increases the number of top-quality embryos in patients undergoing IVF/ICSI cycles
DOI:10.1186/s13048-024-01465-6 by Journal of Ovarian Research in 2024
[1295]
Feasibility and efficacy of a subcutaneous catheter for controlled ovarian stimulation
DOI:10.1016/j.fertnstert.2024.06.022 by Fertility and Sterility in 2024
[1282]
Effectiveness and safety of GnRH antagonist originator and generic in real-world clinical practice: a retrospective cohort study
DOI:10.3389/fendo.2024.1358278 by Frontiers in Endocrinology (Lausanne) in 2024
[1275]
Metagenomic analysis revealed the association between gut microbiota and different ovary responses to controlled ovarian stimulation
DOI:10.1038/s41598-024-65869-6 by Scientific Reports in 2024
[1248]
A modified flexible GnRH antagonist protocol using antagonist early cessation and a gonadotropin step-down approach improves live birth rates in fresh cycles: a randomized controlled trial
DOI:10.1093/humrep/deae145 by Human Reproduction in 2024
[1246]
GnRH agonist early follicular challenge test as a predictor of ovarian response in antagonist cycles for fertility preservation
DOI:10.1038/s41598-024-65059-4 by Scientific Reports in 2024
[1201]
What protocol should not be adopted, and which patients should not be suggested double stimulation in the same ovarian cycle? A randomized controlled trial answers
DOI:10.1093/humrep/deae141 by Human Reproduction in 2024
[1180]
BEYOND Investigators , BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle,
DOI:10.1093/humrep/deae092 by Human Reproduction in 2024
[994]
Webinars
Progestin primed ovarian stimulation: for whom, when and how? An interview with Baris Ata
RBMO Live
New strategies to optimize ovarian stimulation for IVF/ICSI: a window to the future [IVFWW]
IVF WorldWide
Progestin Primed Ovarian Stimulation [IVFWW]
IVF WorldWide
Sub topics related to :Ovarian stimulation.
ID
Course
Add-on treatment options and ART
Growth Hormone supplementation
References related to SubTopic
Xiao-fang Du, Xin-hong Yang, Jing Li, Mengmeng Hao, Yi-hong Guo (2016). Growth hormone co-treatment within a GnRH agonist long protocol improves implantation and pregnancy rates in patients undergoing IVF-ET
Archives of Gynecology and Obstetrics. DOI: 10.1007/s00404-016-4163-1 - ID:1845
Yanrong Chen, Liyuan Tao, Yihua Lin, Xiaoxue Li & Caihong Ma (2020) Outcomes of in vitro fertilization–embryo transfer in women with diminished ovarian reserve after growth hormone pretreatment, Gynecological Endocrinology, DOI: 10.1080/09513590.2020.1737005 - ID:2414
Chen QL, Shuai J, Chen WH, Zhang XD, Pei L, Huang GN, Ye H. Impact of growth hormone supplementation on improving oocyte competence in unexplained poor embryonic development patients of various ages. Gynecol Endocrinol. 2021 Nov 12:1-7. doi: 10.1080/09513590.2021.2000963 - ID:3939
Yovich JL, Hinchliffe PM. A 10-Year Perspective on the Utility of Three Adjuvants Often Used in IVF: Growth Hormone, Melatonin and DHEA. Reproductive Medicine. 2021, 2(4):155-162. doi.org/10.3390/reprodmed2040016 - ID:3940
Keane KN, Ye Y, Hinchliffe PM, Regan SL, Dhaliwal SS, Yovich JL. (2019)Live birth outcomes of vitrified embryos generated under growth hormone stimulation are improved for women categorized as poor-prognosis.
Clin Exp Reprod Med. 2019 Nov 19. doi: 10.5653/cerm.2019.00206 - ID:2319
Altmäe S, Aghajanova L (2019) Growth Hormone and Endometrial Receptivity.
Front Endocrinol (Lausanne). 2019 doi: 10.3389/fendo.2019.00653 - ID:2291
Dosouto C, Calaf J, Polo A, Haahr T, Humaidan P. (2019) Growth Hormone and Reproduction: Lessons Learned From Animal Models and Clinical Trials. Front Endocrinol (Lausanne). 2019 doi: 10.3389/fendo.2019.00404 - ID:2253
Regan SLP, Knight PG, Yovich JL, Arfuso F, Dharmarajan A. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril. 2018 Dec,110(7):1298-1310. doi: 10.1016/j.fertnstert.2018.08.018 - ID:2139
Norman RJ, Hart RJ. Human growth hormone use in poor ovarian response - caution and opportunities. Ther Adv Reprod Health. 2021 Mar 19,15:2633494121999420. doi: 10.1177/2633494121999420 - ID:3941
Hart RJ. Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve. Front Endocrinol (Lausanne). 2019 doi: 10.3389/fendo.2019.00500 - ID:3943
Gleicher N, Darmon SK, Molinari E, Patrizio P, Barad DH. Importance of IGF-I levels in IVF: potential relevance for growth hormone (GH) supplementation. J Assist Reprod Genet. 2022 Jan 23. doi: 10.1007/s10815-021-02379-8 - ID:4202
